Top 10 Rotigotine (Neupro) Generic Manufacturers in United Kingdom
The pharmaceutical market in the United Kingdom has been experiencing notable growth, particularly in the field of generic medications. As of 2022, the UK generic drug market was valued at approximately £12.4 billion, accounting for around 80% of total prescription medicines dispensed in the country. Rotigotine, marketed as Neupro, is a key treatment for Parkinson’s disease and Restless Legs Syndrome, and its generic versions are gaining traction due to the increasing demand for cost-effective treatment options. With a rise in the aging population and heightened prevalence of neurological disorders, the competition among manufacturers of Rotigotine generics is intensifying.
1. Mylan N.V.
Mylan is a global leader in generics and has a significant presence in the UK market. The company has a robust portfolio that includes a generic version of Rotigotine. In 2022, Mylan reported a revenue of $11.6 billion, with generics accounting for a large portion of its sales.
2. Teva Pharmaceuticals
Teva is one of the largest generic pharmaceutical companies in the world. Its generic Rotigotine contributes significantly to its UK operations. Teva’s global revenue reached approximately $16.8 billion in 2022, with generics making up over 50% of this figure, highlighting its importance in the market.
3. Sandoz (Novartis)
Sandoz, a division of Novartis, is a prominent generic manufacturer known for its high-quality products. In the UK, Sandoz’s generic Rotigotine is well-regarded. With a market share of around 6% in the UK generics sector, Sandoz reported revenues of approximately $10 billion globally in 2022.
4. Accord Healthcare
Accord Healthcare is a significant player in the UK generic market, focusing on biosimilars and complex generics. Its generic Rotigotine has gained traction, contributing to its overall revenue of about £1.5 billion in 2022, reflecting a steady growth trajectory.
5. Actavis (Teva)
As part of Teva Pharmaceuticals, Actavis’ generic offerings include Rotigotine. The company has shown strong sales performance, contributing to Teva’s overall success. Actavis has a market presence that is vital for generic drugs in the UK, particularly in neurological treatments.
6. Lupin Pharmaceuticals
Lupin is known for its broad range of generic medications. The company has made strides in the UK market with its generic Rotigotine, contributing to its overall revenue of $2.6 billion in 2022. Lupin’s focus on high-quality generics has positioned it favorably among competitors.
7. Hikma Pharmaceuticals
Hikma is a Middle Eastern multinational that has established a significant presence in the UK. The company’s generic Rotigotine has been well received, with Hikma reporting total revenues of $2.1 billion, largely driven by its generic segment.
8. Zydus Cadila
Zydus Cadila is a notable Indian pharmaceutical company with a growing footprint in the UK. Its generic Rotigotine offers an affordable alternative for patients, contributing to the company’s global revenue of approximately $2.5 billion in 2022.
9. Aurobindo Pharma
Aurobindo Pharma is another major Indian player in the UK generics market. The company’s generic Rotigotine is a part of its extensive portfolio, which helped it achieve a revenue of around $2.1 billion in 2022, with generics being a significant contributor.
10. Generics UK (part of the AAH Pharmaceuticals)
Generics UK, under the umbrella of AAH Pharmaceuticals, focuses on providing cost-effective medicines. The company’s generic Rotigotine is a key product that has solidified its market position, contributing to AAH’s overall success in the generics market.
Insights and Trends
The market for Rotigotine generics in the UK is expected to expand due to increasing healthcare costs and the growing prevalence of chronic conditions such as Parkinson’s disease. According to recent forecasts, the UK generic drug market is projected to grow at a CAGR of 7.5% through 2026. The competitive landscape among manufacturers is intensifying, with companies focusing on innovation and quality to capture market share. The push towards biosimilars and complex generics is likely to drive future growth, as more patients seek affordable treatment options without compromising quality. As the aging population continues to rise, the demand for effective treatments like Rotigotine will remain crucial, paving the way for sustained growth in this sector.
Related Analysis: View Previous Industry Report
